Roivant Sciences Ltd

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Roivant Sciences reports strong Q1 earnings and explores new opportunities

Roivant Sciences demonstrated strong financial performance, with positive results for key programs and a substantial cash position. While facing challenges in patent litigation and DTC campaign optimization, the company has opportunities to leverage payer work, explore new therapeutic potentials, and capitalize on transaction opportunities.

ROIV reports positive trial results and potential in autoimmune diseases

ROIV's earnings call highlights positive trial results, potential in autoimmune diseases, and upcoming Phase III study results. The company acknowledges challenges in proving efficacy in lupus but is optimistic about brepocitinib's potential in various indications.

Roivant Sciences doubles revenue in Q3, VTAMA gains traction

Roivant Sciences delivered strong financial results and progress in its pipeline, particularly with the successful launch of VTAMA and enrollment in key studies.
While facing challenges in market penetration and patient behavior trends, the company's strategic focus on innovation and financial discipline positions it for future success.
By leveraging opportunities in expanding indications, advancing pipeline assets, and strategic collaborations, Roivant is poised for sustained growth and value creation.

Roivant Sciences reports robust Q4 earnings and strategic growth outlook

Roivant Sciences delivered a strong financial performance with notable achievements in clinical programs and a robust cash position, indicating stability and growth potential.
While facing challenges in patient consent for biomarker analysis and legal uncertainties, the company is strategically positioned to leverage opportunities in expanding its pipeline and exploring new markets.
With a focus on balancing operational challenges and pursuing strategic growth initiatives, Roivant Sciences remains well-positioned for future success in the biopharmaceutical industry.

Roivant Sciences excels in Q1 2024 with promising autoimmune therapies

Roivant Sciences demonstrated strong performance and promising results in Q1 2024 across multiple programs
Brepocitinib's unique mechanism positions it as a potential leader in autoimmune therapies, with significant market opportunities
Capital decisions post-Immunovant data and pricing strategy alignment present challenges for Roivant
Opportunities lie in rapid commercial launches, blockbuster potential in orphan indications, and prescription acceleration strategies

Roivant Sciences excels in Q2 with $7B cash post-sale

Roivant Sciences delivered a solid performance in Q2 2024, showcasing financial strength, positive clinical outcomes, and strategic focus on value creation. While facing challenges in margin optimization and market competition, the company is well-positioned to leverage opportunities in unmet medical needs and strategic partnerships for growth.

Roivant Sciences reports strong Q3 performance and outlines growth plans

Roivant Sciences showcased strong performance with key successes and efficient development models. The company faces challenges in certain clinical trials but remains optimistic about growth opportunities. By focusing on strategic growth and efficient execution, Roivant aims to capitalize on its promising pipeline and commercial potential.

Roivant Sciences excels in Q4, eyes blockbuster sales and strategic partnerships

Roivant Sciences is strategically positioned with a focus on maximizing pipeline opportunities, prioritizing data-driven decisions, and capitalizing on the differentiation potential of brepocitinib.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Roivant shares finished more than 20% higher on Tuesday after Immunovant, in which Roivant holds a 56.5% stake, released positive data from an early-stage study of its key asset IMVT-1402, a FcRn inhibitor being developed to treat a range of autoimmune diseases. Analysts at Jefferies raised their price target on Roivant stock following Immunovant's data release from $14 to $16 and awarded it a 'Buy' rating.

Roivant stock could go higher on monetization potential of ‘blockbuster' assets

Immunovant Inc

There was a bumper boost for stock in two Nasdaq-listed biotechs premarket after an experimental antibody treatment was revealed to have blockbuster potential. Shares of Immunovant surged 59% after the company revealed encouraging data from an early-stage study of its key asset, IMVT-1402, being developed to treat a host of autoimmune diseases.

Immunovant and Roivant jump as new drug shapes up to become blockbuster

Markets moved lower on Tuesday, giving up some gains from Monday. Immunovant released positive trial data that sent its shares soaring.

These 2 Biotech Stocks Are Bucking a Down Market Tuesday

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in IgG in initial data from a Phase 1 clinical trial in healthy adults, with no dose-related changes in serum albumin or LDL-C, bolstering IMVT-1402 as a potential best-in-class neonatal fragment crystallizable receptor (FcRn) inhibitor.

Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Roivant, a biopharmaceutical firm, focuses on inflammation and immunology, especially VTAMA for dermatology, showing significant growth. With strong financials, clinical successes, and a $9.72B market cap, Roivant has consistently outperformed the S&P 500 and is projecting robust revenue growth. Considering its momentum, clinical outcomes, and strategic vision, the recommendation remains a "Buy" for Roivant with emphasis on investor risk appetite.

Skin In The Game: Behind Roivant's Significant Rise

Roivant Sciences (NASDAQ: ROIV) stock price has entered a major bull run as investors remain optimistic about the company's future. The shares surged to a high of $12.67 on Friday, reaching its highest level since December 2021.

Roivant Sciences: Is this Vivek Ramaswamy's biotech stock a buy?

ACADIA Pharma

Baker Bros. Advisors has been steadily buying Acadia Pharmaceuticals and Roivant Sciences this year.

2 Supercharged Growth Stocks Billionaires Can't Stop Buying

BASEL, Switzerland and LONDON and NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced the “Redemption Fair Market Value” to be used in connection with the previously announced redemption of its outstanding public warrants (the “Public Warrants”) and private placement warrants (the “Private Placement Warrants” and, together with the Public Warrants, the “Warrants”). The Redemption Fair Market Value will be used to determine the number of Roivant common shares (the “Common Shares”) that will be issued in connection with a Make-Whole Exercise (as defined below) of a Warrant, subject to the terms of the Warrant Agreement (as defined below).

Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants

Roivant Sciences Ltd. (NASDAQ:ROIV ) Q1 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Stephanie Lee - Vice President, Special Projects Matthew Gline - Chief Executive Officer Mayukh Sukhatme - President and Chief Investment Officer Conference Call Participants Brian Chen - JPMorgan David Risinger - Leerink Robyn Karnauskas - Truist Securities Louise Chen - Cantor Dennis Ding - Jefferies Yaron Werber - Cowen Douglas Tsao - H.C.

Roivant Sciences Ltd. (ROIV) Q1 2023 Earnings Call Transcript

Roivant Sciences shares traded modestly higher after the inflammation and immunology-focused biopharmaceutical company reported fiscal first quarter financial results that fell short of expectations for both earnings and sales.   For the three months ended June 30, 2023, the company reported a loss per share of $0.38, $0.10 lower than the Street estimate of a loss per share of $0.28.

Roivant Sciences earnings come in below Street estimates despite VTAMA sales growth

Biotech stock Roivant — founded by presidential candidate Vivek Ramaswamy — reported steep losses and lighter sales.

Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales

BASEL, Switzerland and LONDON and NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2023, and provided an update on the business.

Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update

CRISPR Therapeutics

Legend Biotech

With everyone being an expert these days, the concept of top analyst biotech picks might seem suspect at first glance. While we depend on Wall Street's spectrum of expert guidance to establish a frame of reference, they can get some calls embarrassingly wrong.

3 Biotech Stocks That Analysts Are Drooling Over

Aurora Innovation

BGC Group Inc

GoodRx Holdings

Genworth Financial

Hecla Mining

Joby Aviation

Nikola

Opendoor

Transocean

Rocket Lab USA

Investors are even willing to dip into the cheap-stock territory outside the S&P 500 — and it's paying off handsomely so far.

11 Revived Stocks That Traded For $5 Or Less Are Now Worth Billions

BASEL, Switzerland and LONDON and NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will redeem all of its outstanding public warrants (the “Public Warrants”) and private placement warrants (the “Private Placement Warrants” and, together with the Public Warrants, the “Warrants”) to purchase Roivant's common shares (the “Common Shares”) pursuant to its Warrant Agreement dated September 30, 2021 with Equiniti Trust Company, LLC (formerly American Stock Transfer & Trust Company, LLC) as successor warrant agent (the “Warrant Agent”) (the “Warrant Agreement”), that remain outstanding following 5:00 p.m. New York City Time on September 1, 2023 (the “Redemption Date”) for a redemption price of $0.10 per Warrant (the “Redemption Price”).

Roivant Announces Redemption of Outstanding Warrants

Viking Therapeutics

Growth stocks have returned to form this year. Roivant Sciences and Viking Therapeutics are two growth plays that should interest risk-tolerant investors.

2 Magnificient Growth Stocks I'm Buying in August

Amgen

Arcturus Therapeutics

The biotech industry is constantly evolving due to being on the cutting edge of the healthcare industry's research and development. Large biotech companies such as Johnson and Johnson (NYSE: JNJ ), Merck (NYSE: MRK ), and AbbVie (NYSE: ABBV ) offer investors steady and continual growth as well as decent dividends.

3 Biotech Stocks for Getting Rich in 2023

BridgeBio Pharma Inc

BridgeBio Pharma is slated to announce late-stage results for an important pipeline candidate on Monday. Roivant Sciences might be close to a major asset sale that could spark a hefty rally in its shares.

2 Nasdaq Stocks That Could Soar This Week

Shares of Roivant ROIV rose almost 12% on Thursday after a Wall Street Journal (WSJ) article reported that Roche RHHBY was close to buying ROIV's inflammatory bowel disease (IBD) candidate, RVT-3101, for more than $7 billion.

Roivant (ROIV) Up on Reports of Colitis Drug Sale to Roche

Roivant Sciences is in talks to sell an experimental drug that can treat debilitating stomach diseases in a deal that could be valued at more than $7 billion.

Vivek Ramaswamy's pharmacy firm to sell experimental drug in $7B deal

Roche Holding AG

Roche is in discussions to buy a stomach-disease treatment from Roivant for around $7 billion. The report sent ROIV stock surging Friday.

Roivant Surges As Roche Reportedly Considers $7 Billion Drug Takeover

Acadia Pharmaceuticals Inc.'s stock ACAD, -0.23% surged 18% in premarket trading after the company expanded drug rights to a treatment for a rare neurological disorder.

Acadia stock rallies on drug news as Roivant also climbs, while Leslie's, Theseus shares plunge and more moving stocks

Biotech company Roivant Sciences is nearing a deal to sell an experimental drug to treat inflammatory bowel diseases including ulcerative colitis and Crohn's disease to Roche in a deal that could be valued at more than $7 billion, the Wall Street Journal reported on Thursday.

Roivant in talks to sell bowel disease drug to Roche in over $7 bln deal - WSJ

Shares of Roivant Sciences Ltd. ROIV, +1.58% surged in the extended session Thursday following a report that Roche Holding ROG, +0.62% was close to buying an experimental drug from the biotech company.

Roivant stock rallies on report of pending drug sale: WSJ

Roivant, started by presidential candidate Vivek Ramaswamy, could seal a deal in coming days

News for Roivant Sciences Ltd Stock (ROIV)